Glioblastoma, renal cell carcinoma, and metastatic HER2-negative breast cancer are other cancer types in which the administration of bevacizumab is assessed for treatment [51,52,53,54]. Here, ERBB2 is linked to hereditary clear cell renal cell carcinoma.